Quanta Pharma Retatrutide 50mg is a triple agonist that activates the GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation. Lab verified 99.84% purity.
Independently Lab Verified
Three reports across two independent laboratories
Quanta Pharma Retatrutide 50mg is a pharmaceutical-grade triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This lyophilised vial from Quanta Pharma offers researchers a high-purity compound for advanced metabolic and weight management studies. Independently verified across two laboratories: Analiza Białek confirmed 99% purity and 54.25mg content (August 2026), and Janoshik confirmed 99.84% purity (September 2025). Available for UK delivery with fast dispatch.
Quanta Pharma Retatrutide 50mg Specifications
Retatrutide 50mg by Quanta Pharma
Quanta Pharma Retatrutide Research Benefits
- Triple receptor action - Targets GLP-1, GIP, and Glucagon receptors for the most comprehensive metabolic research available
- Superior weight management - Clinical trials showed greater weight reduction compared to dual agonists like Tirzepatide
- Enhanced fat oxidation - Glucagon receptor activation promotes direct fat burning and energy expenditure
- Glycemic control - Researched for improving insulin sensitivity and glucose metabolism
- Extended half-life - Approximately 6 days allows for once-weekly administration in research protocols
- Dual lab verified - Independently tested by both Analiza Białek and Janoshik for confirmed purity and content
How Quanta Pharma Retatrutide Works
Quanta Pharma Retatrutide is a triple agonist peptide that simultaneously activates three key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the Glucagon receptor. This unique triple-action approach sets it apart from all other incretin-based peptides.
The GLP-1 and GIP receptor activation enhances insulin secretion, reduces appetite, and slows gastric emptying. The addition of Glucagon receptor agonism is what makes Quanta Pharma Retatrutide truly unique, as it directly stimulates fat oxidation, increases energy expenditure, and promotes hepatic fat reduction. This three-pronged approach delivers superior metabolic effects in research settings.
Quanta Pharma Retatrutide vs Tirzepatide vs Semaglutide
Semaglutide targets only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. Quanta Pharma Retatrutide goes further by targeting all three receptors: GLP-1, GIP, and Glucagon. Clinical research has demonstrated that this triple agonist approach produces the most significant weight reduction results of any incretin-based compound studied to date, making Quanta Pharma Retatrutide the most advanced option for metabolic research.
Why Choose Quanta Pharma Retatrutide?
Quanta Pharma is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. Each vial of Quanta Pharma Retatrutide undergoes rigorous quality control and is independently verified across two laboratories. Analiza Białek confirmed 99% purity with 54.25mg content in August 2026, and Janoshik's blind screen confirmed 99.84% purity with 62.40mg content in September 2025. Both tests confirm overfilled vials that deliver more than the 50mg label claim.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification:
- For use by qualified research personnel only
- Keep detailed records of usage and storage as per UK research regulations
Legal Notice: This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.
